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Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are
well tolerated as continuous daily oral therapy. We review the evidence that justifies
the repurposing of PARPi to block the proliferation of severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) and combat the life-threatening sequelae of
coronavirus disease 2019 (COVID-19) by several mechanisms. PARPi can effectively
decrease IL-6, IL-1 and TNF-α levels (key interleukins in SARS-CoV-2-induced cyto-
kine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine
experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic
phenotype. PARPi may also counteract SARS-CoV-2-induced and inflammation-
induced cell death and support cell survival. PARPi is effective in animal models of
acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung
injury. PARPi may potentiate the effectiveness of tocilizumab, anakinra, sarilumab,
adalimumab, canakinumab or siltuximab therapy. The evidence suggests that PARPi
would benefit COVID-19 patients and trials should be undertaken.
Abbreviations: ARDS, acute respiratory distress syndrome; AIF, apoptosis-inducing factor; COPD, chronic obstructive pulmonary disease; CoVs, coronaviruses; COVID-19, coronavirus disease
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1 | CHARACTERISTICS OF THE SEVERE
ACUTE RESPIRATORY SYNDROME
CORONAVIRUS 2 (CORONAVIRUS DISEASE
2019) INFECTION
The newly emerging coronavirus disease, coronavirus disease 2019
(COVID-19), is caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (Zhu et al., 2020). The SARS-CoV-2
belongs to the Coronaviridae family, being genetically related to
the human pathogen SARS-CoV-1 and MERS-CoV and to a number of
bat-origin coronaviruses (CoVs) (Lu et al., 2020). SARS-CoV-2 is an
enveloped virus that has a positive-sense single-stranded RNA (ssRNA+)
genome of nearly 30,000 nucleotide in length (Zhu et al., 2020).
The first site of viral infection is the upper respiratory tract. At a
later stage of infection, the virus may disseminate to and replicate in
the lower respiratory tract (Zhu et al., 2020). Viral RNA and infectious
virus can be found in the nasopharyngeal swab and the sputum. In
addition, infection of the gastrointestinal tract has been reported and
infectious viruses can be isolated from faecal specimens (Xiao
et al., 2020). The virus uses the ACE2 as cellular receptor and a type II
transmembrane serine protease, TMPRSS2, as co-factor that activates
the attachment protein of SARS-CoV-2 (Lu et al., 2020) to aid viral
entry into epithelial cells of the respiratory and in the gastrointestinal
tract (Xiao et al., 2020). In the majority of the cases, patients have
very mild symptoms. However, a considerable portion of the patients
develop severe symptoms and require intensive care and mechanical
ventilation; this patient group shows an increased risk for death (Chen
et al., 2020;Guan et al., 2020; Huang et al., 2020). The risk factors for
complications and mortality include pre-existing cardiovascular, meta-
bolic or neoplastic diseases and older age (Nikolich-Zugich
et al., 2020; Zhou et al., 2020). Men have higher chance for develop-
ing severe symptoms, as well as, for fatal outcome (Guan et al., 2020;
Huang et al., 2020).
Although the pathogenesis of COVID-19 is not fully understood,
immunopathological mechanisms are thought to play an important
role. A detrimental sequel of SARS-CoV-2 virus infection is a cytokine
storm (also called cytokine release syndrome or macrophage over-
activation syndrome) that occurs after the elimination of the virus and
culminates in multiple organ failure (Mehta et al., 2020; Shi
et al., 2020). Cytokine storm may be responsible for a considerable
fraction of adverse outcomes in SARS-CoV-2 infection (Shi
et al., 2020). The reason for the absence of the adaptive response is
unknown. In clinical practice, tocilizumab, an antibody against IL-6
(Luo et al., 2020; McGonagle, Sharif, O'Regan, & Bridgewood, 2020;
Toniati et al., 2020) and anakinra, an IL-1 receptor antagonist (Adam
Monteagudo, Boothby, & Gertner, 2020; McGonagle et al., 2020),
were used successfully to cope with SARS-Cov-2-induced cytokine
storm suggesting the involvement of these interleukins. Other drugs,
primarily used in rheumatological settings, are also suggested to be
used to block cytokine storm (Ceribelli et al., 2020).
The current treatment options in SARS-CoV-2 infection are
limited to drugs empirically tested in the clinical setting. The
unmet medical need posed by SARS-CoV-2 infection calls for rapid
repositioning of available drugs. These drugs are mostly antiviral drugs
(e.g. lopinavir–ritonavir combinational therapy and remdesivir) or
anti-inflammatory drugs, as noted above. None of the current
COVID-19 treatments are supported by prospective randomized clin-
ical trials and therefore, all of these treatments should be considered
with caution. The World Health Organization (WHO) initiated a
large-scale drug repositioning study to rapidly assess the most prom-
ising candidates to fight SARS-CoV-2 pandemic. In this position
review, we are reviewing the applicability of poly (ADP-ribose) poly-
merase inhibitors (PARPi) and their possible interactions with known
therapeutic options in SARS-CoV-2 infection.
2 | BRIEF INTRODUCTION TO THE
BIOLOGY OF POLY (ADP-RIBOSE)
POLYMERASES (PARPs)
PARP/ARTD enzymes constitute a family of 17 members in humans
(PARP1–PARP17) (Ame, Spenlehauer, & de Murcia, 2004). When acti-
vated, PARPs cleave their substrate, NAD+, and couple the resulting
ADP-ribose units onto acceptor proteins forming monomers, oligo-
mers or polymers of ADP-ribose. The polymer of ADP-ribose is called
PAR. The large, negatively charged monomers, oligomers or polymers
heavily impact on the behaviour of target proteins and a huge number
of proteins were shown to be ADP-ribosylated or PARylated on multi-
ple different amino acids (Bai, 2015). In addition, ADP-ribose units can
serve as binding surface for proteins (Tartier et al., 2003).
Macrodomain-containing proteins constitute a small protein fam-
ily (Karlberg, Langelier, Pascal, & Schuler, 2013). Macrodomains can
bind to ADP-ribose units and some can hydrolyse ADP-ribose units
upon binding (Karlberg et al., 2013). Through binding or hydrolysing
ADP-ribose, macrodomain-containing proteins can translate ADP-
ribosylation signals into cellular adaptation programmes. Macro-
domains can be found in all domains of life, including viruses (Fehr,
Jankevicius, Ahel, & Perlman, 2018) and, more specifically, CoVs
(Grunewald et al., 2019).
PARP1 is responsible for 85–90% of cellular PARP activity,
PARP2 is responsible for 10–15%, while the rest of the enzymes share
the remainder of all cellular PARP activity (Schreiber et al., 2002).
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Active PARPs represent a large burden on cellular NAD+ levels (Sims,
Berger, & Berger, 1983). Although, originally, excess PARP activation
is linked to DNA damage-associated pathologies, recent advances
showed that PARP activity under physiological conditions also repre-
sents a large burden on cellular NAD+ levels (Bai et al., 2011; Bai
et al., 2011; Mohamed, Hajira, Pardo, & Boriek, 2014).
PARP1, PARP2 and PARP3 can be activated by binding to irregu-
lar or damaged DNA (Bai, 2015) that is often the result of ROS or
reactive nitrogen species (RNS) production under inflammatory condi-
tions (Bai & Virag, 2012). The activation of PARP1, PARP2 and PARP3
is vital for initiating DNA repair and the resolution of irregular DNA
structures and modulating chromatin structure. Through these, certain
PARP isoforms (chiefly, PARP1) are involved in recombination and
transcription events that encompass changes to DNA structure
(Bai, 2015). Importantly, PARP2 can bind to RNA, which may activate
the enzyme (Leger, Bar, Savic, Santoro, & Hottiger, 2014). There are
other pathways to activate PARPs involving signal transduction path-
ways (Bai, 2015). PARP enzymes were shown to be involved in tran-
scription, mRNA handling and polypeptide elongation (for
comprehensive reviews, see Kim, Challa, Jones, & Kraus, 2020).
PARP enzymes are involved in a wide variety of cellular pro-
cesses; among these, their impact in cell death, immune function
(Bai & Virag, 2012; Fehr et al., 2020), antiviral response (Fehr
et al., 2018; Fehr et al., 2020), transcription, translation (Kim
et al., 2020) and autophagy (Rodríguez-Vargas, Oliver-Pozo, &
Dantzer, 2019) are relevant for our discussion. PARPi that are in cur-
rent clinical use (olaparib, rucaparib, niraparib and talazoparib) are
inhibitors of PARP1, PARP2 and PARP3 (Wahlberg et al., 2012).
3 | THERAPEUTIC POTENTIAL OF PARPi
3.1 | Anti-inflammatory effects of PARPi and
modulation of cell death—Combatting the cytokine
storm
The protective effect of PARPi, which is applicable to non-oncological
models of inflammation, was first suggested by Nathan Berger's group
nearly 40 years ago (Sims et al., 1983). They noted that DNA damage-
induced cell death was associated with PARP activation, resulting in
massive depletion of its substrate, NAD+, and consequently ATP that
resulted in necrosis. Depletion of these pools was prevented in the
presence of a PARPi and necrosis reduced. Subsequently, it has also
been shown that the product of the PARP reaction, that is, PAR, can
also trigger apoptosis-inducing factor (AIF) release that promotes a
specific programmed cell death pathway called “parthanatos”
(Fatokun, Dawson, & Dawson, 2014). Relevant to inflammatory nor-
mal tissue damage in general and acute respiratory distress syndrome
(ARDS) in particular is the role of oxidative and nitrosative stress,
which is integral to inflammation and causes DNA strand breakage
that massively activates PARP (Bai & Virag, 2012; Ke et al., 2019).
Indeed, PARP can actively increase and prolong inflammation through
a vicious cycle of ROS/RNS-induced DNA damage, PARP-mediated
necrosis and increase in inflammatory cytokines (Figure 1). PARPi
have been shown to limit inflammation-induced normal tissue dam-
age, including acute lung injury, in animal models (reviewed in
Pazzaglia & Pioli, 2019; Virág, 2005).
Reactive species production increases in SARS-CoV-2 (COVID-19)
infection (Kouhpayeh et al., 2020; Sawalha, Zhao, Coit, & Lu, 2020;
Wang et al., 2020; Zhang, Wu, Li, Zhao, & Wang, 2020) that
makes PARP activation and PARP activation-mediated cell death
likely. Pharmacological PARP inhibition is likely to reduce cell death
under these conditions as suggested by the study on another ssRNA
(+) virus, the Zika virus. Zika virus-induced cell death was effectively
blocked by PARP inhibition (Xu et al., 2019). The source of the reac-
tive species can be diverse, stemming from activated immune
(e.g. macrophages) or dysfunctional cells. Interestingly,
the nucleocapsid protein of SARS-CoV-1 can induce ROS
production in non-immune cells, so that can be a pathway in the case
of SARS-Cov-2 as well (Zhang et al., 2007). In fact, a pre-publication
paper (Heer et al., 2020) already suggested that SARS-CoV-2
infection induces PARP activity.
PARP1 is the best characterized member of the PARP family from
the perspective of immune processes. PARP1 seems to have mostly
pro-inflammatory properties in terms of Th1- and Th2-mediated pro-
cesses (Bai & Virag, 2012; Fehr et al., 2020). PARP2 has limited role in
pro-inflammatory processes (Bai & Virag, 2012). Pharmacological
PARP inhibition is generally anti-inflammatory. PARP1 is involved in
regulating innate and adaptive immunity (Fehr et al., 2020) through
mediating signal transduction and transcription events in multiple
immune cell lines that is translated to differential expression of cyto-
kines and chemokines, as well as their receptors (Bai & Virag, 2012;
Fehr et al., 2020). In humans, there is evidence that the polymorphism
in PARP1 (V762A) that confers reduced activity is associated with
reduced risk of asthma (Ozaydin et al., 2014). PARP activity is
increased in the lung tissues of asthmatic patients and in mouse
models, the PARPi, olaparib, prevents asthma, indicating that the
extrapolations from preclinical models to human conditions are valid
(Ghonim et al., 2015). Also, PARP inhibition confers protection to the
lungs upon acute lung injury inflicted by various noxae (burns, smoke
inhalation, bacterial infection, etc.) (Hamahata et al., 2012; Murakami
et al., 2004) in an NF-κB-dependent fashion (Ahmad et al., 2015;
Wang et al., 2013). Various PARPi (3-AB, PJ-34 and INO-1001) have
been shown to be protective in various preclinical models of acute
respiratory distress syndrome by reducing the production of inflam-
matory mediators and preventing the depletion of NAD+ and ATP and
also the deterioration of barrier function that may contribute to exu-
date formation in acute respiratory distress syndrome (reviewed in
Virág, 2005). The most common animal model of human acute lung
injury/acute respiratory distress syndrome is intratracheal instillation
of LPS. PARP plays an important role in the pathogenesis of LPS-
mediated acute respiratory distress syndrome damage by a variety of
mechanisms. Both genetic disruption of PARP1 and inhibition of PARP
ameliorate acute respiratory distress syndrome and acute respiratory
distress syndrome-associated tissue damage (reviewed in Sethi,
Dharwal, & Naura, 2017). Following LPS administration, olaparib not
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only reduced inflammatory cell infiltration in the lung and pulmonary
oedema and exudate but also reduced secondary kidney injury
(Kapoor, Singla, Sahu, & Naura, 2015). Relevance to human lung dis-
ease comes from the observation that in cases of chronic obstructive
pulmonary disease (COPD), plasma NAD+ is low and DNA damage,
PARP activity and the percentage of PAR positive lymphocytes were
higher than in control subjects (Hageman et al., 2003; Oit-Wiscombe,
Virag, Soomets, & Altraja, 2013).
PARP inhibition has an additional lung protective feature. PARPi
are able to reduce lung fibrosis, a common sequel of SARS-Cov-2 lung
inflammation, in different preclinical animal models (Carlile
et al., 2016; Hoyt & Lazo, 1992, 1993; Lucarini et al., 2017). PARP
activity in idiopathic lung fibrosis patients was higher than in healthy
controls (Hu et al., 2013), suggesting that the findings of the animal
models can be translated to the human situation.
As we noted above, a major reason of mortality in SARS-CoV-2
(COVID-19) infection is the macrophage overactivation that
leads to cytokine storm and, consequently, to multi-organ
failure (Vaninov, 2020). To date, IL-6 and IL-1 were implicated in
SARS-CoV-2 (COVID-19)-induced cytokine storm (Conti et al., 2020;
McGonagle et al., 2020), however the involvement of TNF-α is also
likely. PARPi, including olaparib, can reduce the expression of IL-6 in
multiple organs, including the lung (Ghonim et al., 2015; Kim
et al., 2008; Liaudet et al., 2002; Pagano et al., 2007; Sahu, Narota, &
Naura, 2020) in animal models. Importantly and in good agreement
with the previous dataset, pharmacological PARP inhibition using
INO-1001 in humans reduced serum IL-6 and C-reactive protein
(CRP) levels (Morrow et al., 2009), further reinforcing the notion that
data from preclinical studies can be translated to humans.
Another interleukin implicated in eliciting the cytokine storm in
SARS-CoV-2 (COVID-19) infection is IL-1 (Conti et al., 2020;
McGonagle et al., 2020). PARPi, including olaparib, can decrease IL-1β
expression in animal models (Liaudet et al., 2002; Mabley et al., 2001;
Sahu et al., 2020; Sethi, Sharma, & Naura, 2019) that, again points out
the applicability of PARPi to dampen IL-1 expression in humans.
Finally, pharmacological PARP inhibition, including with the clinically
approved PARPi, olaparib, reduced TNF-α levels in the lungs in various
animal models of lung inflammation (Cuzzocrea et al., 2002; Kim
et al., 2008; Liaudet et al., 2002; Sahu et al., 2020; Virag et al., 2004).
The data we presented suggest that PARP inhibition can counter-
act inflammation-induced cell death and possibly counteracts the
acute respiratory distress syndrome-like features and cytokine storm
through blocking macrophage overactivation (cytokine storm) through
down-regulating the expression of IL-6, IL-1, and TNF-α in humans.
These events represent a vicious circle that is sustained by PARP1
activation. Therefore, PARPi can break the chain of events at multiple
loci (as suggested in Jagtap & Szabo, 2005) and exert cytoprotective
effects on the pulmonary epithelial and endothelial cells.
3.2 | Ventilator-induced lung injury
SARS-Cov-2-infected patients requiring intensive care often need
mechanical ventilation over extended periods (Huang et al., 2020).
Pharmacological inhibition of PARP reduced the inflammatory compo-
nent of ventilation-induced lung damage in a murine model (Kim
et al., 2008). Furthermore, in another rat preclinical model of severe
acute lung injury, the PARPi PJ-34 protected the kidney from injury
F IGURE 1 The role of PARP in inflammation-induced tissue damage. Infection-induced ROS and reactive nitrogen species (RNS) cause DNA
strand breakage. This activates PARP1 and PARP2, which generates PAR that can lead to apoptosis-inducing factor (AIF) release leading to cell
death by parthanatos. This reaction also depletes NAD+ and subsequently ATP leading to necrosis, which causes further inflammation and
activation of immune cells (e.g. macrophages) leading to more ROS and RNS generation and, so, a vicious cycle of further PARP activation and
downstream consequences. PARP activation also stimulates the production of inflammatory cytokines, such as IL-6, further contributing to this
vicious cycle. All of this can essentially be blocked by the use of a PARPi
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following mechanical ventilation (Vaschetto et al., 2010). Similar find-
ings were obtained in an ovine model, where acute lung injury was
induced by smoke inhalation and local Pseudomonas aeruginosa coloni-
zation (Murakami et al., 2004). It appears that in ventilation-induced
lung damage (VILI), PARP inhibition breaks a similar vicious cycle as in
acute respiratory distress syndrome or other inflammatory models
(Jagtap & Szabo, 2005). The similarity of the findings in rodent and
large animal models supports the potential for translating these find-
ings to the human situation.
3.3 | Antiviral effects of PARPs and its interactions
with CoVs
Several members of the PARP family are involved in host–virus inter-
actions, and by our current understanding, most PARP enzymes have
antiviral properties (Fehr et al., 2020; Grunewald, Shaban, Mackin,
Fehr, & Perlman, 2020). PARPs impact on multiple steps of the viral
life cycle. These steps are mostly related to the nucleic acid-binding
properties of PARPs. PARPs can interfere with viral integration,
recombination, and transcription (Fehr et al., 2020); however, these
are not relevant in the context of CoVs.
PARP13 was shown to be induced upon orthomyxovirus or
alphavirus infection and to have protective function (Fehr et al., 2020).
Interferon (IFN) treatment induces a set of PARP enzymes PARP9,
PARP10, PARP12 and PARP14 in cells (Grunewald et al., 2019). These
PARP enzymes inhibit viral translation probably through ADP-
ribosylating key cellular proteins (Grunewald et al., 2019).
Members of the virus families Coronaviridae, Togaviridae and
Hepeviridae encode macrodomain proteins that bind to and hydrolyse
ADP-ribose from proteins and are critical for optimal replication and
virulence (Grunewald et al., 2019; Grunewald et al., 2020). The con-
served CoV macrodomain in SARS-CoV was found to play a role in
viral replication and to suppress IFN and cytokine production
(Grunewald et al., 2019; Grunewald et al., 2020). Interestingly, the
nucleocapsid protein of SARS-CoV and a number of other CoVs are
ADP-ribosylated (Grunewald, Fehr, Athmer, & Perlman, 2018), yet the
significance of this post-translational modification is unexplored.
Since PARPi have preference towards PARP1, PARP2 and PARP3
(Wahlberg et al., 2012), it is unlikely that PARPi treatment would
interfere with the antiviral effects of the minor PARP isoforms. An
interesting and potentially relevant finding is that another PARPi,
PJ34, can form a complex with the nucleocpasid protein of the human
CoV CoV-OC43 and, hence, can hinder its RNA-binding affinity (Lin
et al., 2014).
3.4 | Interactions with drugs proposed for
COVID-19 therapy
The WHO initiated a large-scale drug repurposing clinical trial enti-
tled “Solidarity” (WHO, 2020). In the frame of this trial, four treat-
ment schemes will be assessed:- (a) remdesivir, (b) lopinavir–
ritonavir combination, (c) chloroquine/hydroxychloroquine and
(d) IFN-β. Empirical clinical data suggest the applicability of these
biological therapy drugs to combat cytokine storm. Here, we will
evaluate the potential for PARPi in combination with the drugs
investigated in the Solidarity trial. Combination therapy is particu-
larly advantageous, since it requires lower doses with better tolera-
bility of the components. As we noted earlier, none of the current
COVID-19 treatments are supported by prospective randomized
clinical trials, and therefore, all of these treatments should be con-
sidered with caution.
To date, PARPi have not been reported to interact with ritona-
vir, lopinavir, or remdesivir. IFN-β has pleiotropic antiviral actions,
and therefore, probably, IFN-β can induce the antiviral function
of PARPs.
Chloroquine and hydroxychloroquine are antimalarial and anti-
rheumatic drugs that were assessed in small-scale cohorts in
France and China (Gao, Tian, & Yang, 2020; Gautret et al., 2020).
Although criticism was raised concerning the available studies and
the potential cardiotoxicity of both drugs, the WHO included chlo-
roquine and hydroxychloroquine to kick off a multicentre, large
population study. Chloroquine and hydroxychloroquine probably
block the processing of SARS-CoV-2 by blocking the acidification
of the vesicles containing the virus, in a process biochemically simi-
lar to the process of autophagy. Of note, the genetic or
pharmacological inhibition of PARP1 blocks the early steps of
autophagy (Rodríguez-Vargas et al., 2019). Furthermore, the genetic
or pharmacological inhibition of PARP2 blocks the degradation of
the cargo of autophagic vesicles mimicking the action of chloro-
quine (Janko et al., 2020). From these observations, one may
extrapolate that PARPi could potentiate the antiviral effects of
chloroquine or hydroxychloroquine and could be exploited to
achieve dose reduction of chloroquine or hydroxychloroquine. It is
also of note that ADP-ribosylation-mediated autophagic processes
were found to be important in the pathogenesis of other microor-
ganisms such as Legionella in high-profile studies (e.g. Kalayil
et al., 2018). Nevertheless, links between PARPi and chloroquine
are purely hypothetical.
IL-6 is a key interleukin in sustaining cytokine storm following
SARS-CoV-2 infection (Zhang et al., 2020). Studies have shown that
anti-IL-6 immunotherapy using tocilizumab was beneficial for patients
(Luo et al., 2020; McGonagle et al., 2020). As we noted earlier, PARP
inhibition was shown to reduce IL-6 expression in humans; therefore,
it is possible that PARP inhibition could also potentiate the effects of
anti-IL-6 (tocilizumab and siltuximab) or anti-IL-6 receptor (sarilumab)
treatment.
Preclinical data suggest that PARPi can reduce IL-1 (Liaudet
et al., 2002; Mabley et al., 2001; Sethi et al., 2019) and TNF-α expres-
sion (Kim et al., 2008; Liaudet et al., 2002; Virag et al., 2004). It is pos-
sible therefore that PARPi could potentiate canakinumab (IL-1β
antibody), anakinra (IL-1 receptor antagonist) and adalimumab (TNF-α
antibody) therapy.
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4 | AVAILABLE PARPi AND THEIR CURRENT
SCOPE OF USE
Four PARPi are approved by the Food and Drug Administration (FDA)
and European Medicines Agency (EMA) for cancer therapy. Although
the original rationale for their development was to overcome DNA
repair-mediated resistance to DNA damaging anticancer therapy, their
approval has been as single agents exploiting tumour-specific defects
in the cDNA repair pathway homologous recombination repair (HRR)
by a process known as synthetic lethality.
Currently, PARPi are only approved for cancer therapy as single
agents (Table 1). The first to be approved was olaparib, now called
Lynparza®. Originally approved by the FDA at the end of 2014 at a
dose of 400 mg twice daily in capsule formulation, it is now approved
in tablet formulation at 300 mg twice daily for maintenance (including
front-line) therapy in ovarian cancer. It is also approved at the same
dose and schedule for metastatic breast and pancreatic cancer in indi-
viduals with germline BRCA mutations. Also approved in ovarian can-
cer are rucaparib (Rubraca®) at 600 mg p.o. twice daily and niraparib
(Zejula®) 300 mg p.o. once daily. Talazoparib (Talzenna®) is the most
potent of all the PARPi and has been approved at dose of only 1 mg
daily for germline BRCA-mutated metastatic breast cancer. Veliparib is
a less potent PARPi that has so far failed to show sufficient single-
agent activity for approval but has been in advanced clinical trial alone
and in combination with other anticancer agents for over a decade.
Due to their tumour-specific synthetic lethality, their toxicity as
monotherapies is mild and manageable. The common adverse effects
are fatigue, gastrointestinal (nausea/vomiting, abdominal pain, and
TABLE 1 Human studies involving Phase IV PARP inhibitors
Drug name
Dose and
schedule Indication FDA approval NCT# and trial details Reference






December 2014 NCT00753545 Phase II (Ledermann et al., 2012)















(Moore et al., 2018;
Pujade-Lauraine et
al., 2017)




January 2018 NCT02000622 Phase III (Robson et al., 2017)






December 2019 NCT02184195 POLO
Phase III
(Golan et al., 2019)

















(Coleman et al., 2017;
Kristeleit et al., 2017;
Oza et al., 2017;
Swisher et al., 2017)


















October 2019 NCT02354586 QUADRA
Phase III
(Moore et al., 2019)




October 2018 NCT01945775 EMBRCA
Phase III








NCT02106546 (Ramalingam et al., 2017)
Note: The table encompasses only the clinically approved PARPi.
Abbreviation: FDA, Food and Drug Administration.
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diarrhoea) and haematological (neutropenia for olaparib, anaemia for
rucaparib and talazoparib, and thrombocytopenia for niraparib), mostly
Grade 1–2 (LaFargue, Dal Molin, Sood, & Coleman, 2019; Murthy &
Muggia, 2019). Myelodysplastic syndrome and acute myeloid leukae-
mia have also been noted, but this may have been caused mainly by
prior chemotherapy, particularly platinum-based therapies (Murthy &
Muggia, 2019). In combination with DNA damaging therapies, the safe
dose is much lower and the tolerated schedules are much shorter. For
example, the approved dose of rucaparib (Rubraca®) is 600 mg p.o. 2×
daily continuously and the safe dose in combination with carboplatin
is 240 mg once daily for 14 days every 21 days and only 18 mgm−2
i.v. (equivalent to 60 mg p.o.) for 5 days every 28 days in combination
with temozolomide (Curtin, 2020).
It is anticipated that the doses needed for non-oncological dis-
eases, for example, acute respiratory distress syndrome, are likely to
be lower (and hence less toxic) for two reasons. Firstly, the doses
found to be effective preclinically in non-oncological models are 1–2
orders of magnitude lower than the monotherapy doses used in can-
cer models (reviewed in Berger et al., 2018). This is likely to reflect
the intracellular concentrations needed to maintain NAD+ pool from
excessive depletion versus those needed to completely block repair
for a sustained period. Secondly, the approved doses are largely based
on dose escalation Phase I trials where the endpoint is tolerability,
which may not be appropriate for a tumour-specific drug and may be
well in excess of the effective dose.
5 | CONCLUDING REMARKS
The evidence we describe above indicates that PARPi may have bene-
ficial effects in SARS-CoV-2 infection and its sequelae by preventing
macrophage overactivation and the subsequent cytokine storm, as
well as by protecting cells against cell death. It is also of note that
PARPi were protective against risk factors for bad clinical outcomes
of SARS-CoV-2 infection, such as cardiovascular and metabolic dis-
eases (Bai, 2015). Importantly, PARPi are cytoprotective in the central
nerve system (Fatokun et al., 2014) and the cardiovascular system
(Bai, 2015), the systems that are damaged in COVID-19 patients with
bad clinical outcome.
Of particular interest regarding COVID-19 is the sex bias of the
mortality statistics. Men are more than twice as likely to die as women
(Guan et al., 2020; Huang et al., 2020). Previous research has shown
that men have on average 40% higher PARP activity than women, at
least in their peripheral blood mononuclear cells (PBMCs), with similar
sex differences in mice (Mabley et al., 2005; Zaremba et al., 2011). In
most preclinical studies where the protective effects of PARPi were
evaluated, only male animals have been used. However, in those stud-
ies where both sexes were included, the protective effects of PARPi
were less pronounced in females (reviewed in Berger et al., 2018;
Curtin & Szabo, 2013). There are no data for sex differences in PARP
activity in human lung tissue due to the difficulty of obtaining viable
normal lung tissue. However, in humans following traumatic brain
injury, men were 2.6 times more likely than women to have elevated
PAR-modified proteins in their CSF after comparable levels of
trauma and strikingly similar to the studies in PBMCs, the mean PAR
level was approximately 40% higher in males than females (Sarnaik
et al., 2010).
Currently, there are over 600 registered clinical trials investigating
COVID-19, not one of which includes a PARPi. The preclinical evi-
dence suggests that 5–10% of the currently approved PARPi doses
would be sufficient/effective and tolerable. Finally, given there has
been no FDA-approved therapy for acute respiratory distress syn-
drome (reviewed in Standiford & Ward, 2016), we believe that the
preclinical data and scientific rationale justify investigations with (low
dose?) PARPi.
6 | SEARCH STRATEGY AND SELECTION
CRITERIA
References to this review were identified through the prior knowl-
edge of the authors that was complemented by systematic search of
PubMed by using the combinations “PARP IL-6,” “PARP IL-1,” “PARP
TNFa/alpha,” “PARP virus,” “PARP SARS,” “virus macrodomain,”
“PARP fibrosis lung,” “PARP remedsivir,” “PARP ritonavir,” “PARP
lopinavir,” “PARP chloroquine,” and “PARP hydroxychloroquine.” Arti-
cles published in English were included with no restriction on
publication date.
6.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in
the Concise Guide to PHARMACOLOGY 2019/20 (Alexander
et al., 2019).
ACKNOWLEDGEMENTS
Our work was supported by grants from the Hungarian Scientific
Research Fund NKFIH (K123975, GINOP-2.3.2-15-2016-0000,
EFOP-3.6.2-16-2017-00008, GINOP-2.3.2 STAY ALIVE, and 20765-
3/2018/FEKUTSTRAT) and by the Faculty of Medicine at the
University of Debrecen. The research was financed by the Higher
Education Institutional Excellence Program (NKFIH-1150-6/2019) of
the Ministry of Innovation and Technology in Hungary, within the
framework of the Biotechnology thematic programme of the Univer-
sity of Debrecen.
CONFLICT OF INTEREST
N.C. reports grants from AICR during the conduct of the study. In
addition, N.C. has a patent WO 2005/012305 A2 with royalties paid
to CRUK and Newcastle University and a patent WO/2006/033006
with royalties paid to CRUK and Newcastle University. The other
authors declare no conflicts of interest.




Adam Monteagudo, L., Boothby, A., & Gertner, E. (2020). Continuous
intravenous anakinra infusion to calm the cytokine storm in macro-
phage activation syndrome. ACR Open Rheumatol, 2(5), 276–282.
Ahmad, S. F., Zoheir, K. M., Ansari, M. A., Korashy, H. M., Bakheet, S. A.,
Ashour, A. E., … Attia, S. M. (2015). The role of poly (ADP-ribose)
polymerase-1 inhibitor in carrageenan-induced lung inflammation in
mice. Molecular Immunology, 63(2), 394–405. https://doi.org/10.1016/
j.molimm.2014.09.009
Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L.,
Armstrong, J. F., … Southan, C. (2019). The Concise Guide to PHAR-
MACOLOGY 2019/20: Introduction and other protein targets. British
Journal of Pharmacology, 176(Suppl 1), S1–S20.
Ame, J. C., Spenlehauer, C., & de Murcia, G. (2004). The PARP superfamily.
BioEssays, 26(8), 882–893. https://doi.org/10.1002/bies.20085
Bai, P. (2015). Biology of poly (ADP-ribose) polymerases: The factotums of
cell maintenance. Molecular Cell, 58(6), 947–958. https://doi.org/10.
1016/j.molcel.2015.01.034
Bai, P., Canto, C., Brunyánszki, A., Huber, A., Szántó, M., Cen, Y., …
Auwerx, J. (2011). PARP-2 regulates SIRT1 expression and whole-
body energy expenditure. Cell Metabolism, 13(4), 450–460. https://
doi.org/10.1016/j.cmet.2011.03.013
Bai, P., Cantó, C., Oudart, H., Brunyánszki, A., Cen, Y., Thomas, C., …
Auwerx, J. (2011). PARP-1 inhibition increases mitochondrial metabo-
lism through SIRT1 activation. Cell Metabolism, 13(4), 461–468.
https://doi.org/10.1016/j.cmet.2011.03.004
Bai, P., & Virag, L. (2012). Role of poly (ADP-ribose) polymerases in the
regulation of inflammatory processes. FEBS Letters, 586(21),
3771–3777. https://doi.org/10.1016/j.febslet.2012.09.026
Berger, N. A., Besson, V. C., Boulares, A. H., Burkle, A., Chiarugi, A.,
Clark, R. S., … Szabo, C. (2018). Opportunities for the repurposing of
PARP inhibitors for the therapy of non-oncological diseases. British
Journal of Pharmacology, 175(2), 192–222. https://doi.org/10.1111/
bph.13748
Carlile, G. W., Robert, R., Matthes, E., Yang, Q., Solari, R., Hatley, R., …
Birault, V. (2016). Latonduine analogs restore F508del–cystic fibrosis
transmembrane conductance regulator trafficking through the modula-
tion of poly-ADP ribose polymerase 3 and poly-ADP ribose polymer-
ase 16 activity. Molecular Pharmacology, 90(2), 65–79. https://doi.org/
10.1124/mol.115.102418
Ceribelli, A., Motta, F., De Santis, M., Ansari, A. A., Ridgway, W. M.,
Gershwin, M. E., & Selmi, C. (2020). Recommendations for corona-
virus infection in rheumatic diseases treated with biologic therapy.
Journal of Autoimmunity, 109, 102442. https://doi.org/10.1016/j.
jaut.2020
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., … Zhang, L. (2020).
Epidemiological and clinical characteristics of 99 cases of 2019 novel
coronavirus pneumonia in Wuhan, China: A descriptive study. The Lan-
cet, 395(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)
30211-7
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A.,
Dean, A., … Ledermann, J. A. (2017). Rucaparib maintenance treatment
for recurrent ovarian carcinoma after response to platinum therapy
(ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet, 390(10106), 1949–1961. https://doi.org/10.1016/S0140-
6736(17)32440-6
Conti, P., Ronconi, G., Caraffa, A., Gallenga, C. E., Ross, R., Frydas, I., &
Kritas, S. K. (2020). Induction of pro-inflammatory cytokines (IL-1 and
IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-
CoV-2): Anti-inflammatory strategies. Journal of Biological Regulators &
Homeostatic Agents, 34(2). https://doi.org/10.23812/CONTI-E
Curtin, N., & Szabo, C. (2013). Therapeutic applications of PARP inhibitors:
Anticancer therapy and beyond. Molecular Aspects of Medicine, 6,
1043–1258.
Curtin, N. J. (2020). The development of Rucaparib/Rubraca®: A story of
the synergy between science and serendipity. Cancers, 12(3). https://
doi.org/10.3390/cancers12030564
Cuzzocrea, S., McDonald, M. C., Mazzon, E., Dugo, L., Serraino, I.,
Threadgill, M., … Thiemermann, C. (2002). Effects of 5-amino
isoquinolinone, a water-soluble, potent inhibitor of the activity of poly
(ADP-ribose) polymerase, in a rodent model of lung injury. Biochemical
Pharmacology, 63(2), 293–304. https://doi.org/10.1016/S0006-2952
(01)00864-4
Fatokun, A. A., Dawson, V. L., & Dawson, T. M. (2014). Parthanatos:
Mitochondrial-linked mechanisms and therapeutic opportunities.
British Journal of Pharmacology, 171, 2000–2016. https://doi.org/10.
1111/bph.12416
Fehr, A. R., Jankevicius, G., Ahel, I., & Perlman, S. (2018). Viral macro-
domains: Unique mediators of viral replication and pathogenesis.
Trends in Microbiology, 26(7), 598–610. https://doi.org/10.1016/j.tim.
2017.11.011
Fehr, A. R., Singh, S. A., Kerr, C. M., Mukai, S., Higashi, H., & Aikawa, M.
(2020). The impact of PARPs and ADP-ribosylation on inflammation
and host–pathogen interactions. Genes & Development, 34(5–6),
341–359. https://doi.org/10.1101/gad.334425.119
Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate
has shown apparent efficacy in treatment of COVID-19 associated
pneumonia in clinical studies. Bioscience Trends, 14(1), 72–73. https://
doi.org/10.5582/bst.2020.01047
Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., …
Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treat-
ment of COVID-19: Results of an open-label non-randomized clinical
trial. International Journal of Antimicrobial Agents, 105949. https://doi.
org/10.1016/j.ijantimicag.2020.105949
Ghonim, M. A., Pyakurel, K., Ibba, S. V., Al-Khami, A. A., Wang, J.,
Rodriguez, P., … Boulares, A. H. (2015). PARP inhibition by olaparib or
gene knockout blocks asthma-like manifestation in mice by modulating
CD4+ T cell function. Journal of Translational Medicine, 13, 225.
https://doi.org/10.1186/s12967-015-0583-0
Ghonim, M. A., Pyakurel, K., Ibba, S. V., Wang, J., Rodriguez, P., Al-
Khami, A. A., … Boulares, A. H. (2015). PARP is activated in human
asthma and its inhibition by olaparib blocks house dust mite-induced
disease in mice. Clinical Science (London, England), 129(11), 951–962.
https://doi.org/10.1042/CS20150122
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., …
Kindler, H. L. (2019). Maintenance olaparib for germline BRCA-
mutated metastatic pancreatic cancer. The New England Journal
of Medicine, 381(4), 317–327. https://doi.org/10.1056/NEJMoa
1903387
Grunewald, M. E., Chen, Y., Kuny, C., Maejima, T., Lease, R., Ferraris, D., …
Fehr, A. R. (2019). The coronavirus macrodomain is required to pre-
vent PAsRP-mediated inhibition of virus replication and enhancement
of IFN expression. PLoS Pathogens, 15(5), e1007756
Grunewald, M. E., Fehr, A. R., Athmer, J., & Perlman, S. (2018). The corona-
virus nucleocapsid protein is ADP-ribosylated. Virology, 517, 62–68.
https://doi.org/10.1016/j.virol.2017.11.020
Grunewald, M. E., Shaban, M. G., Mackin, S. R., Fehr, A. R., & Perlman, S.
(2020). Murine coronavirus infection activates the aryl hydrocarbon
receptor in an indoleamine 2,3-dioxygenase-independent manner,
contributing to cytokine modulation and proviral TCDD-inducible-
PARP expression. Journal of Virology, 94(3), e01743-19. https://doi.
org/10.1128/JVI.01743-19
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., …
Zhong, N.-S. (2020). Clinical characteristics of coronavirus disease
2019 in China. New England Journal of Medicine, 382, 1708–1720.
https://doi.org/10.1056/NEJMoa2002032
3642 CURTIN ET AL.
Hageman, G. J., Larik, I., Pennings, H. J., Haenen, G. R., Wouters, E. F., &
Bast, A. (2003). Systemic poly (ADP-ribose) polymerase-1 activation,
chronic inflammation, and oxidative stress in COPD patients. Free Rad-
ical Biology & Medicine, 35(2), 140–148. https://doi.org/10.1016/
S0891-5849(03)00237-5
Hamahata, A., Enkhbaatar, P., Lange, M., Yamaki, T., Sakurai, H.,
Shimoda, K., … Traber, D. L. (2012). Administration of poly (ADP-
ribose) polymerase inhibitor into bronchial artery attenuates pulmo-
nary pathophysiology after smoke inhalation and burn in an ovine
model. Burns, 38(8), 1210–1215. https://doi.org/10.1016/j.burns.
2012.08.021
Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J.,
Ireland, S., … NC-IUPHAR. (2018). The IUPHAR/BPS Guide to PHAR-
MACOLOGY in 2018: Updates and expansion to encompass the new
guide to IMMUNOPHARMACOLOGY. Nucleic Acids Research, 46,
D1091–D1106. https://doi.org/10.1093/nar/gkx1121
Heer, C. D., Sanderson, D. J., Alhammad, Y. M. O., Schmidt, M. S.,
Trammell, S. A. J., Perlman, S., … Brenne, C. (2020). Coronavirus infec-
tion and PARP expression dysregulate the NAD metabolome: A poten-
tially actionable component of innate immunity. bioRxiv. https://doi.
org/10.1101/2020.1104.1117.047480
Hoyt, D. G., & Lazo, J. S. (1992). Murine strain differences in acute lung
injury and activation of poly (ADP-ribose) polymerase by in vitro expo-
sure of lung slices to bleomycin. American Journal of Respiratory Cell
and Molecular Biology, 7(6), 645–651. https://doi.org/10.1165/
ajrcmb/7.6.645
Hoyt, D. G., & Lazo, J. S. (1993). NAD depletion after in vitro exposure of
murine lung slices to bleomycin. Biochemical Pharmacology, 46(10),
1819–1824. https://doi.org/10.1016/0006-2952(93)90588-N
Hu, B., Wu, Z., Hergert, P., Henke, C. A., Bitterman, P. B., & Phan, S. H.
(2013). Regulation of myofibroblast differentiation by poly (ADP-
ribose) polymerase 1. The American Journal of Pathology, 182(1),
71–83. https://doi.org/10.1016/j.ajpath.2012.09.004
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., … Cao, B. (2020). Clini-
cal features of patients infected with 2019 novel coronavirus in
Wuhan. China. Lancet., 395(10223), 497–506. https://doi.org/10.
1016/S0140-6736(20)30183-5
Jagtap, P., & Szabo, C. (2005). Poly (ADP-ribose) polymerase and the thera-
peutic effects of its inhibitors. Nat.Rev.Drug Discov., 4(5), 421–440.
https://doi.org/10.1038/nrd1718
Janko, L., Sari, Z., Kovacs, T., Kis, G., Szanto, M., Antal, M., … Bai, P. (2020).
Silencing of PARP2 blocks autophagic degradation. Cells, 9(2), 380.
https://doi.org/10.3390/cells9020380
Kalayil, S., Bhogaraju, S., Bonn, F., Shin, D., Liu, Y., Gan, N., … Dikic, I.
(2018). Insights into catalysis and function of phosphoribosyl-linked
serine ubiquitination. Nature, 557(7707), 734–738. https://doi.org/10.
1038/s41586-018-0145-8
Kapoor, K., Singla, E., Sahu, B., & Naura, A. S. (2015). PARP inhibitor,
olaparib ameliorates acute lung and kidney injury upon intratracheal
administration of LPS in mice. Molecular and Cellular Biochemistry, 400
(1–2), 153–162. https://doi.org/10.1007/s11010-014-2271-4
Karlberg, T., Langelier, M. F., Pascal, J. M., & Schuler, H. (2013). Structural
biology of the writers, readers, and erasers in mono- and poly (ADP-
ribose) mediated signaling. Molecular Aspects of Medicine, 34(6),
1088–1108. https://doi.org/10.1016/j.mam.2013.02.002
Ke, Y., Wang, C., Zhang, J., Zhong, X., Wang, R., Zeng, X., & Ba, X. (2019).
The role of PARPs in inflammation- and metabolic-related diseases:
Molecular mechanisms and beyond. Cells, 8(9), 1047. https://doi.org/
10.3390/cells8091047
Kim, D. S., Challa, S., Jones, A., & Kraus, W. L. (2020). PARPs and ADP-
ribosylation in RNA biology: From RNA expression and processing to
protein translation and proteostasis. Genes & Development, 34(5–6),
302–320. https://doi.org/10.1101/gad.334433.119
Kim, J. H., Suk, M. H., Yoon, D. W., Kim, H. Y., Jung, K. H., Kang, E. H., …
Kang, K. H. (2008). Inflammatory and transcriptional roles of poly
(ADP-ribose) polymerase in ventilator-induced lung injury. Critical
Care, 12(4), R108. https://doi.org/10.1186/cc6995
Kouhpayeh, S., Shariati, L., Boshtam, M., Rahimmanesh, I., Mirian, M.,
Zeinalian, M., Salari-jazi, A., Khanahmad, N., Damavandi, M. S.,
Sadeghi, P., & Khanahmad, H. (2020). The molecular story of COVID-
19; NAD+ depletion addresses all questions in this infection. Preprints,
https://doi.org/10.20944/preprints202003.200346.v202001
Kristeleit, R., Shapiro, G. I., Burris, H. A., Oza, A. M., LoRusso, P.,
Patel, M. R., … Shapira-Frommer, R. (2017). A phase I–II study of the
oral PARP inhibitor rucaparib in patients with germline BRCA1/2-
mutated ovarian carcinoma or other solid tumors. Clinical Cancer
Research, 23(15), 4095–4106. https://doi.org/10.1158/1078-0432.
CCR-16-2796
LaFargue, C. J., Dal Molin, G. Z., Sood, A. K., & Coleman, R. L. (2019).
Exploring and comparing adverse events between PARP inhibitors.
The Lancet Oncology, 20(1), e15–e28. https://doi.org/10.1016/S1470-
2045(18)30786-1
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I.,
Rustin, G., … Matulonis, U. (2012). Olaparib maintenance therapy in
platinum-sensitive relapsed ovarian cancer. The New England Journal of
Medicine, 366(15), 1382–1392. https://doi.org/10.1056/NEJMoa
1105535
Leger, K., Bar, D., Savic, N., Santoro, R., & Hottiger, M. O. (2014). ARTD2
activity is stimulated by RNA. Nucleic Acids Research, 42(8),
5072–5082. https://doi.org/10.1093/nar/gku131
Liaudet, L., Pacher, P., Mabley, J. G., Virag, L., Soriano, F. G., Hasko, G., &
Szabo, C. (2002). Activation of poly (ADP-Ribose) polymerase-1 is a
central mechanism of lipopolysaccharide-induced acute lung inflam-
mation. Am.J.Respir.Crit Care Med., 165(3), 372–377. https://doi.org/
10.1164/ajrccm.165.3.2106050
Lin, S. Y., Liu, C. L., Chang, Y. M., Zhao, J., Perlman, S., & Hou, M. H.
(2014). Structural basis for the identification of the N-terminal domain
of coronavirus nucleocapsid protein as an antiviral target. Journal of
Medicinal Chemistry, 57(6), 2247–2257. https://doi.org/10.1021/
jm500089r
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K. H., …
Blum, J. L. (2018). Talazoparib in patients with advanced breast cancer
and a germline BRCA mutation. The New England Journal of Medicine,
379(8), 753–763. https://doi.org/10.1056/NEJMoa1802905
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., … Tan, W. (2020). Genomic
characterisation and epidemiology of 2019 novel coronavirus: Implica-
tions for virus origins and receptor binding. The Lancet, 395(10224),
565–574. https://doi.org/10.1016/S0140-6736(20)30251-8
Lucarini, L., Durante, M., Lanzi, C., Pini, A., Boccalini, G., Calosi, L., …
Mannaioni, G. (2017). HYDAMTIQ, a selective PARP-1 inhibitor,
improves bleomycin-induced lung fibrosis by dampening the TGF-
β/SMAD signalling pathway. Journal of Cellular and Molecular Medicine,
21(2), 324–335. https://doi.org/10.1111/jcmm.12967
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020). Tocilizumab treatment
in COVID-19: A single center experience. Journal of Medical Virology,
92(7), 814–818. https://doi.org/10.1002/jmv.25801
Mabley, J. G., Horvath, E. M., Murthy, K. G., Zsengeller, Z., Vaslin, A.,
Benko, R., … Szabo, C. (2005). Gender differences in the endotoxin-
induced inflammatory and vascular responses: Potential role of poly
(ADP-ribose) polymerase activation. The Journal of Pharmacology and
Experimental Therapeutics, 315(2), 812–820. https://doi.org/10.1124/
jpet.105.090480
Mabley, J. G., Jagtap, P., Perretti, M., Getting, S. J., Salzman, A. L., Virag, L.,
… Szabo, C. (2001). Anti-inflammatory effects of a novel, potent inhibi-
tor of poly (ADP-ribose) polymerase. Inflammation Research, 50(11),
561–569. https://doi.org/10.1007/PL00000234
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020). The role
of cytokines including interleukin-6 in COVID-19 induced pneumonia
and macrophage activation syndrome-like disease. Autoimmunity
Reviews, 19(6), 102537.
CURTIN ET AL. 3643
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., &
Manson, J. J. (2020). COVID-19: Consider cytokine storm syndromes
and immunosuppression. Lancet, 395(10229), 1033–1034. https://doi.
org/10.1016/S0140-6736(20)30628-0
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S.,
Redondo, A., … Matulonis, U. A. (2016). Niraparib maintenance ther-
apy in platinum-sensitive, recurrent ovarian cancer. The New England
Journal of Medicine, 375(22), 2154–2164. https://doi.org/10.1056/
NEJMoa1611310
Mohamed, J. S., Hajira, A., Pardo, P. S., & Boriek, A. M. (2014). MicroRNA-
149 inhibits PARP-2 and promotes mitochondrial biogenesis via SIRT-
1/PGC-1α network in skeletal muscle. Diabetes, 63(5), 1546–1559.
https://doi.org/10.2337/db13-1364
Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A.,
Friedlander, M., … DiSilvestro, P. (2018). Maintenance olaparib in
patients with newly diagnosed advanced ovarian cancer. The New
England Journal of Medicine, 379(26), 2495–2505. https://doi.org/10.
1056/NEJMoa1810858
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N.,
Fleming, G. F., … Monk, B. J. (2019). Niraparib monotherapy for late-
line treatment of ovarian cancer (QUADRA): A multicentre, open-label,
single-arm, phase 2 trial. The Lancet Oncology, 20(5), 636–648. https://
doi.org/10.1016/S1470-2045(19)30029-4
Morrow, D. A., Brickman, C. M., Murphy, S. A., Baran, K., Krakover, R.,
Dauerman, H., … Salzman, A. L. (2009). A randomized, placebo-
controlled trial to evaluate the tolerability, safety, pharmacokinetics,
and pharmacodynamics of a potent inhibitor of poly (ADP-ribose)
polymerase (INO-1001) in patients with ST-elevation myocardial
infarction undergoing primary percutaneous coronary intervention:
Results of the TIMI 37 trial. Journal of Thrombosis and Thrombolysis, 27
(4), 359–364.
Murakami, K., Enkhbaatar, P., Shimoda, K., Cox, R. A., Burke, A. S.,
Hawkins, H. K., … Traber, D. L. (2004). Inhibition of poly (ADP-ribose)
polymerase attenuates acute lung injury in an ovine model of sepsis.
Shock, 21(2), 126–133. https://doi.org/10.1097/01.shk.0000108397.
56565.4a
Murthy, P., & Muggia, F. (2019). PARP inhibitors: Clinical development,
emerging differences and the current therapeutic issues. Cancer Drug
Resist, 2, 665–679.
Nikolich-Zugich, J., Knox, K. S., Rios, C. T., Natt, B., Bhattacharya, D., &
Fain, M. J. (2020). SARS-CoV-2 and COVID-19 in older adults: What
we may expect regarding pathogenesis, immune responses, and out-
comes. Geroscience, 42(2), 505–514. https://doi.org/10.1007/s11357-
11020-00186-11350
Oit-Wiscombe, I., Virag, L., Soomets, U., & Altraja, A. (2013). Increased
DNA damage in progression of COPD: A response by poly (ADP-
ribose) polymerase-1. PLoS ONE, 8(7), e70333. https://doi.org/10.
1371/journal.pone.0070333
Oza, A. M., Tinker, A. V., Oaknin, A., Shapira-Frommer, R., McNeish, I. A.,
Swisher, E. M., … Kristeleit, R. S. (2017). Antitumor activity and safety
of the PARP inhibitor rucaparib in patients with high-grade ovarian
carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Inte-
grated analysis of data from Study 10 and ARIEL2. Gynecologic Oncol-
ogy, 147(2), 267–275. https://doi.org/10.1016/j.ygyno.2017.08.022
Ozaydin, A., Akbas, F., Aksoy, F., Yildirim, Y. S., Demirhan, H., Karakurt, F.,
… Kanigur Sultuybek, G. (2014). Investigation of poly (ADP-ribose)
polymerase-1 genetic variants as a possible risk for allergic rhinitis.
Genetic Testing and Molecular Biomarkers, 18(1), 57–61. https://doi.
org/10.1089/gtmb.2013.0363
Pagano, A., Métrailler-Ruchonnet, I., Aurrand-Lions, M., Lucattelli, M.,
Donati, Y., & Argiroffo, C. B. (2007). Poly (ADP-ribose) polymerase-1
(PARP-1) controls lung cell proliferation and repair after hyperoxia-
induced lung damage. American Journal of Physiology. Lung Cellular and
Molecular Physiology, 293(3), L619–L629. https://doi.org/10.1152/
ajplung.00037.2007
Pazzaglia, S., & Pioli, C. (2019). Multifaceted role of PARP-1 in DNA repair
and inflammation: Pathological and therapeutic implications in cancer
and non-cancer diseases. Cells, 9(1), 41. https://doi.org/10.3390/
cells9010041
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V.,
Penson, R. T., Oza, A. M., … Pautier, P. (2017). Olaparib tablets as
maintenance therapy in patients with platinum-sensitive, relapsed
ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A
double-blind, randomised, placebo-controlled, phase 3 trial. The Lan-
cet Oncology, 18(9), 1274–1284. https://doi.org/10.1016/S1470-
2045(17)30469-2
Ramalingam, S. S., Blais, N., Mazieres, J., Reck, M., Jones, C. M., Juhasz, E.,
… Gorbunova, V. (2017). Randomized, placebo-controlled, phase II
study of veliparib in combination with carboplatin and paclitaxel for
advanced/metastatic non-small cell lung cancer. Clinical Cancer
Research, 23(8), 1937–1944. https://doi.org/10.1158/1078-0432.
CCR-15-3069
Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., …
Conte, P. (2017). Olaparib for metastatic breast cancer in patients with
a germline BRCA mutation. The New England Journal of Medicine, 377
(6), 523–533. https://doi.org/10.1056/NEJMoa1706450
Rodríguez-Vargas, J. M., Oliver-Pozo, F. J., & Dantzer, F. (2019). PARP1
and poly(ADP-ribosyl)ation signaling during autophagy in response to
nutrient deprivation. Oxidative Medicine and Cellular Longevity, 2019,
2641712.https://doi.org/10.1155/2019/2641712
Sahu, B., Narota, A., & Naura, A. S. (2020). Pharmacological inhibition of
poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury
associated cognitive deficits potentially through suppression of inflam-
matory response. European Journal of Pharmacology, 877, 173091.
https://doi.org/10.1016/j.ejphar.2020.173091
Sarnaik, A. A., Conley, Y. P., Okonkwo, D. O., Barr, T. L., Fink, E. L.,
Szabo, C., … Clark, R. S. (2010). Influence of PARP-1 polymorphisms in
patients after traumatic brain injury. Journal of Neurotrauma, 27(3),
465–471. https://doi.org/10.1089/neu.2009.1171
Sawalha, A. H., Zhao, M., Coit, P., & Lu, Q. (2020). Epigenetic dysregulation
of ACE2 and interferon-regulated genes might suggest increased
COVID-19 susceptibility and severity in lupus patients. Clinical Immu-
nology, 215, 108410. https://doi.org/10.1016/j.clim.2020
Schreiber, V., Ame, J. C., Dolle, P., Schultz, I., Rinaldi, B., Fraulob, V., … de
Murcia, G. (2002). Poly (ADP-ribose) polymerase-2 (PARP-2) is
required for efficient base excision DNA repair in association with
PARP-1 and XRCC1. The Journal of Biological Chemistry, 277(25),
23028–23036. https://doi.org/10.1074/jbc.M202390200
Sethi, G. S., Dharwal, V., & Naura, A. S. (2017). Poly(ADP-ribose)polymer-
ase-1 in lung inflammatory disorders: A review. Frontiers in Immunol-
ogy, 8, 1172. https://doi.org/10.3389/fimmu.2017.01172
Sethi, G. S., Sharma, S., & Naura, A. S. (2019). PARP inhibition by olaparib
alleviates chronic asthma-associated remodeling features via modulat-
ing inflammasome signaling in mice. IUBMB Life, 71(7), 1003–1013.
https://doi.org/10.1002/iub.2048
Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, J., Huang, X., … Melino, G.
(2020). COVID-19 infection: The perspectives on immune responses.
Cell Death and Differentiation, 27, 1451–1454. https://doi.org/10.
1038/s41418-41020-40530-41413
Sims, J. L., Berger, S. J., & Berger, N. A. (1983). Poly (ADP-ribose) polymer-
ase inhibitors preserve nicotinamide adenine dinucleotide and adeno-
sine 50-triphosphate pools in DNA-damaged cells: Mechanism of
stimulation of unscheduled DNA synthesis. Biochemistry, 22(22),
5188–5194. https://doi.org/10.1021/bi00291a019
Standiford, T. J., & Ward, P. A. (2016). Therapeutic targeting of acute lung
injury and acute respiratory distress syndrome. Translational Research,
167(1), 183–191. https://doi.org/10.1016/j.trsl.2015.04.015
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., …
McNeish, I. A. (2017). Rucaparib in relapsed, platinum-sensitive high-
grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre,
3644 CURTIN ET AL.
open-label, phase 2 trial. The Lancet Oncology, 18(1), 75–87. https://
doi.org/10.1016/S1470-2045(16)30559-9
Tartier, L., Spenlehauer, C., Newman, H. C., Folkard, M., Prise, K. M.,
Michael, B. D., … de, M. G. (2003). Local DNA damage by proton
microbeam irradiation induces poly (ADP-ribose) synthesis in mamma-
lian cells. Mutagenesis, 18(5), 411–416. https://doi.org/10.1093/
mutage/geg015
Toniati, P., Piva, S., Cattalini, M., Garrafa, E., Regola, F., Castelli, F., …
Latronico, N. (2020). Tocilizumab for the treatment of severe COVID-
19 pneumonia with hyperinflammatory syndrome and acute respira-
tory failure: A single center study of 100 patients in Brescia, Italy.
Autoimmunity Reviews, 19(7), 102568. https://doi.org/10.1016/j.
autrev.2020.102568
Vaninov, N. (2020). In the eye of the COVID-19 cytokine storm. Nature
Reviews. Immunology, 6(10), 20–305.
Vaschetto, R., Kuiper, J. W., Musters, R. J., Eringa, E. C., Della Corte, F.,
Murthy, K., … Plotz, F. B. (2010). Renal hypoperfusion and impaired
endothelium-dependent vasodilation in an animal model of VILI: The
role of the peroxynitrite-PARP pathway. Critical Care, 14(2), R45.
https://doi.org/10.1186/cc8932
Virág, L. (2005). Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Pharmacological Research, 52(1), 83–92. https://doi.org/10.1016/j.
phrs.2005.02.012
Virag, L., Bai, P., Bak, I., Pacher, P., Mabley, J. G., Liaudet, L., … Szabo, C.
(2004). Effects of poly (ADP-ribose) polymerase inhibition on inflam-
matory cell migration in a murine model of asthma. Med.Sci.Monit., 10
(3), BR77–BR83.
Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A.,
Thorsell, A. G., … Weigelt, J. (2012). Family-wide chemical profiling
and structural analysis of PARP and tankyrase inhibitors. Nature Bio-
technology, 30(3), 283–288. https://doi.org/10.1038/nbt.2121
Wang, G., Huang, X., Li, Y., Guo, K., Ning, P., & Zhang, Y. (2013). PARP-1
inhibitor, DPQ, attenuates LPS-induced acute lung injury through
inhibiting NF-κB-mediated inflammatory response. PLoS ONE, 8(11),
e79757. https://doi.org/10.1371/journal.pone.0079757
Wang, Y. X., Ma, J. R., Wang, S. Q., Zeng, Y. Q., Zhou, C. Y., Ru, Y. H., …
Li, H. (2020). Utilizing integrating network pharmacological approaches
to investigate the potential mechanism of Ma Xing Shi Gan Decoction
in treating COVID-19. European Review for Medical and Pharmacologi-
cal Sciences, 24(6), 3360–3384. https://doi.org/10.26355/eurrev_
202003_20704
World Health Organization (2020). “Solidarity” clinical trial for COVID-19




Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., & Shan, H. (2020). Evidence for
gastrointestinal infection of SARS-CoV-2. Gastroenterology, 158,
1831–1833.e3. https://doi.org/10.1053/j.gastro.2020.1002.1055
Xu, G., Li, S., Liu, X., Gao, P., Chen, X., Wang, H., … Zhang, F. (2019). PARP-
1 mediated cell death is directly activated by ZIKV infection. Virology,
537, 254–262. https://doi.org/10.1016/j.virol.2019.08.024
Zaremba, T., Thomas, H. D., Cole, M., Coulthard, S. A., Plummer, E. R., &
Curtin, N. J. (2011). Poly (ADP-ribose) polymerase-1 (PARP-1)
pharmacogenetics, activity and expression analysis in cancer patients
and healthy volunteers. The Biochemical Journal, 436(3), 671–679.
https://doi.org/10.1042/BJ20101723
Zhang, C., Wu, Z., Li, J. W., Zhao, H., & Wang, G. Q. (2020). The cytokine
release syndrome (CRS) of severe COVID-19 and interleukin-6 recep-
tor (IL-6R) antagonist tocilizumab may be the key to reduce the mor-
tality. International Journal of Antimicrobial Agents, 55, 105954.
https://doi.org/10.1016/j.ijantimicag.2020
Zhang, L., Wei, L., Jiang, D., Wang, J., Cong, X., & Fei, R. (2007). SARS-CoV
nucleocapsid protein induced apoptosis of COS-1 mediated by the
mitochondrial pathway. Artificial Cells, Blood Substitutes, and Immobili-
zation Biotechnology, 35(2), 237–253. https://doi.org/10.1080/
10731190601188422
Zhang, R., Wang, X., Ni, L., Di, X., Ma, B., Niu, S., … Reiter, R. J. (2020).
COVID-19: Melatonin as a potential adjuvant treatment. Life Sciences,
250, 117583. https://doi.org/10.1016/j.lfs.2020.117583
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., … Cao, B. (2020). Clinical
course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: A retrospective cohort study. Lancet,
395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)
30566-3
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., … Tan, W. (2020). A
novel coronavirus from patients with pneumonia in China, 2019. New
England Journal of Medicine, 382(8), 727–733. https://doi.org/10.
1056/NEJMoa2001017
How to cite this article: Curtin N, Bányai K, Thaventhiran J, Le
Quesne J, Helyes Z, Bai P. Repositioning PARP inhibitors for
SARS-CoV-2 infection(COVID-19); a new multi-pronged
therapy for acute respiratory distress syndrome? Br
J Pharmacol. 2020;177:3635–3645. https://doi.org/10.1111/
bph.15137
CURTIN ET AL. 3645
